Robert Cohen1, Alioska Escorcia2, Farzana Tasmin2, Ana Lima1, Yulia Lin1,3,4, Lani Lieberman2,3,4, Jacob Pendergrast2,3,4, Jeannie Callum1,3,4, Christine Cserti-Gazdewich2,3,4. 1. Department of Clinical Pathology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. 2. Department of Clinical Pathology, University Health Network, Toronto, Ontario, Canada. 3. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. 4. Quality, Utilization, Efficacy & Safety of Transfusion (QUEST) Research Collaborative, Toronto, Ontario, Canada.
Abstract
BACKGROUND: Febrile nonhemolytic transfusion reactions (FNHTRs) are characterized by a post-transfusion temperature rise (of ≥ 1°C, to ≥ 38°C) or chills/rigors unrelated to the underlying condition. FNHTRs are provoked by inflammatory cytokines in the product or by host antileukocyte antibodies against residual donor leukocytes. FNHTRs are among the most commonly reported transfusion disturbances and are generally deemed nonserious events. However, their impact on patients and hospitals may be underestimated. STUDY DESIGN AND METHODS: A search through two hemovigilance databases identified all known possible-to-definite FNHTRs over 3 years (2013-2015) at four academic hospitals using prestorage leukoreduced components. FNHTRs were assessed for frequency by product (red blood cells [RBCs], platelets [PLTs], intravenous immunoglobulin), diagnostics (bedside, chest imaging, serology, microbiology), and management (medications, disposition change). The definition of FNHTR was derived from Canada's Transfusion-Transmitted Injuries Surveillance System. RESULTS: For 437 FNHTRs, the overall per-product rate across all sites was 0.24%, or 0.17% with RBCs alone and 0.25% with PLTs alone. One-third of patients had significant fevers (≥ 39.0°C or a rise by ≥ 2.0°C). Approximately one-quarter underwent chest imaging within 48 hours, and 79% had blood cultures. A hospital admission directly attributable to the FNHTR, to exclude other causes of fever, occurred in 15% of FNHTR outpatients. CONCLUSION: An analysis of FNHTRs reveals a substantial burden of postreaction clinical activity in addition to the disturbance itself. Efforts to avoid this adverse event may save resources, reduce patient distress, and encourage compliance with more restrictive transfusion strategies.
BACKGROUND: Febrile nonhemolytic transfusion reactions (FNHTRs) are characterized by a post-transfusion temperature rise (of ≥ 1°C, to ≥ 38°C) or chills/rigors unrelated to the underlying condition. FNHTRs are provoked by inflammatory cytokines in the product or by host antileukocyte antibodies against residual donor leukocytes. FNHTRs are among the most commonly reported transfusion disturbances and are generally deemed nonserious events. However, their impact on patients and hospitals may be underestimated. STUDY DESIGN AND METHODS: A search through two hemovigilance databases identified all known possible-to-definite FNHTRs over 3 years (2013-2015) at four academic hospitals using prestorage leukoreduced components. FNHTRs were assessed for frequency by product (red blood cells [RBCs], platelets [PLTs], intravenous immunoglobulin), diagnostics (bedside, chest imaging, serology, microbiology), and management (medications, disposition change). The definition of FNHTR was derived from Canada's Transfusion-Transmitted Injuries Surveillance System. RESULTS: For 437 FNHTRs, the overall per-product rate across all sites was 0.24%, or 0.17% with RBCs alone and 0.25% with PLTs alone. One-third of patients had significant fevers (≥ 39.0°C or a rise by ≥ 2.0°C). Approximately one-quarter underwent chest imaging within 48 hours, and 79% had blood cultures. A hospital admission directly attributable to the FNHTR, to exclude other causes of fever, occurred in 15% of FNHTR outpatients. CONCLUSION: An analysis of FNHTRs reveals a substantial burden of postreaction clinical activity in addition to the disturbance itself. Efforts to avoid this adverse event may save resources, reduce patient distress, and encourage compliance with more restrictive transfusion strategies.
Authors: E A Gehrie; N H Roubinian; D Chowdhury; D J Brambilla; E L Murphy; J L Gottschall; Y Wu; P M Ness; R G Strauss; J E Hendrickson Journal: Vox Sang Date: 2017-12-25 Impact factor: 2.144
Authors: Michele M Loi; Marguerite Kelher; Monika Dzieciatkowska; Kirk C Hansen; Anirban Banerjee; F Bernadette West; Crystal Stanley; Matthew Briel; Christopher C Silliman Journal: Transfusion Date: 2018-09-01 Impact factor: 3.157
Authors: Jitsuda Sitthi-Amorn; Emily Denton; Erin Harper; Delia Carias; Saman Hashmi; Sakshi Bami; Allison Ast; Taylor Landry; Kenneth L Pettit; Shilpa Gorantla; Anna Vinitsky; Yan Zheng; Liza-Marie Johnson Journal: Pediatr Qual Saf Date: 2022-06-14
Authors: Megan E McClosky; Dorothy Cimino Brown; Nicole M Weinstein; Nicole Chappini; Michael T Taney; Kimberly Marryott; Mary Beth Callan Journal: J Vet Intern Med Date: 2018-10-11 Impact factor: 3.333